Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Mural fails to paint a convincing picture for nemvaleukin
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
